Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Add like
Add dislike
Add to saved papers

Increased frequency of HLA-B44 in recurrent sinopulmonary infections (RESPI).

To test whether MHC alleles associated with common variable immune deficiency (CVID) might also be over-represented in patients with normal serum immunoglobulin levels who suffer with recurrent sinopulmonary infections (RESPI), we identified 62 consecutive RESPI patients and compared their HLA-B and HLA-DR antigen frequencies to those of 60 consecutive patients with CVID, 1627 Alabama Caucasian bone marrow donors, and 997,230 published US Caucasians. Either HLA-B44, -B8, -DR3(17), or -DR7 was present in 74% of the RESPI and 85% of the CVID patients. HLA-B44 prevalence in particular proved identical between RESPI and CVID. When compared to US Caucasians, the increased prevalence of the four HLA alleles proved significant at P < 0.0001, P < 0.0001, P = 0.0005, and P = 0.02, respectively. When compared to Alabama Caucasians, only the increased prevalence of HLA-B44 achieved statistical significance (P = 0.0001). Inheritance of HLA-B44 may yield susceptibility to recurrent sinopulmonary infection even in the presence of normal serum immunoglobulin levels.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app